Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 209

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Fluvoxamine versus other anti-depressive agents for depression

Open access
Omori, Ichiro M, Watanabe, Norio, Nakagawa, Atsuo, Cipriani, Andrea, Barbui, Corrado, McGuire, Hugh, Churchill, Rachel, Furukawa, Toshi A · 2010 · Cochrane Database of Systematic Reviews

Abstract

BACKGROUND: Fluvoxamine, one of the oldest selective serotonin reuptake inhibitors (SSRIs), is prescribed to patients with major depression in many countries. Several studies have previously reviewed the efficacy and tolerability of fluvoxamine for the treatment of major depression. However, these reviews are now outdated. OBJECTIVES: Our objective is to evaluate the effectiveness, tolerability and side effect profile of fluvoxamine for major depression in comparison with other anti-depressive agents, including tricyclics (TCAs), heterocyclics, other SSRIs, SNRIs, other newer agents and other conventional psychotropic drugs. SEARCH STRATEGY: We searched the Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register. Trial databases and ongoing trial registers in North America, Europe, Japan and Australia, were handsearched for randomised controlled trials. We checked reference lists of the articles included in the review, previous systematic reviews and major textbooks of affective disorder for published reports and citations of unpublished research. The date of last search was 31 August 2008. SELECTION CRITERIA: We included all randomised controlled trials, published in any language, that compared fluvoxamine with any other active antidepressants in the acute phase treatment of major depression. DATA COLLECTION AND ANALYSIS: Two independent review authors inspected citations and abstracts, obtained papers, extracted data and assessed the risk of bias of included studies. We analysed dichotomous data using odds ratios (ORs) and continuous data using the standardised mean difference (SMD). A random effects model was used to combine studies. MAIN RESULTS: A total of 54 randomised controlled trials (n = 5122) were included. No strong evidence was found to indicate that fluvoxamine was either superior or inferior to other antidepressants regarding response, remission and tolerability. However, differing side effect profiles were evident, especially with regard to gastrointestinal side effects of fluvoxamine when compared to other antidepressants. For example, fluvoxamine was generally associated with a higher incidence of vomiting/nausea (versus imipramine, OR 2.23, CI 1.59 to 3.14; versus clomipramine, OR 2.13, CI 1.06 to 4.27; versus amitriptyline, OR 2.86, CI 1.31 to 2.63). AUTHORS' CONCLUSIONS: We found no strong evidence that fluvoxamine was either superior or inferior to any other antidepressants in terms of efficacy and tolerability in the acute phase treatment of depression. However, differing side effect profiles were evident. Based on these findings, we conclude that clinicians should focus on practical or clinically relevant considerations, including these differences in side effect profiles.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd006114.pub2

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Research works printed but not linked: 217

  1. Amore, 1989, Double-blind comparison of fluvoxamine and imipramine in depressed patients, Current Therapeutic Research, Clinical & Experimental, 46, 815
  2. Ansseau, 1991, Interest of a loading dose of milnacipran in endogenous depressive inpatients. Comparison with the standard regimen and with fluvoxamine, European Neuropsychopharmacology, 1, 113, 10.1016/0924-977X(91)90712-4 · DOI
  3. Ansseau, 1991, Interest of a loading dose of milnacipran in endogenous depressive inpatients. Comparison with the standard regimen and with fluvoxamine, European Neuropsychopharmacology, 1, 113, 10.1016/0924-977X(91)90712-4 · DOI
  4. Ansseau, 1993, A double-blind comparison of paroxetine and fluvoxamine in major depression, European Neuropsychopharmacology, 3, 323, 10.1016/0924-977X(93)90099-8 · DOI
  5. Ansseau, 1994, Controlled comparison of paroxetine and fluvoxamine in major depression, Human Psychopharmacology, 9, 329, 10.1002/hup.470090502 · DOI
  6. Asakura, 2005, A randomized, double-blind study of fluvoxamine maleate in patients with depression or depressive state: A comparison in anticholinergic effects and cardiovascular adverse reactions between fluvoxamine maleate and imipramine hydrochloride, Japanese Pharmacology and Therapeutics, 33, 773
  7. Barrelet, 1991, Multicenter study comparing efficacy and tolerance of moclobemide and fluvoxamine in hospitalized and ambulatory patients with severe depressive episodes, Schweizerische Rundschau fur Medizin Praxis, 80, 524
  8. Bocksberger, 1993, Comparison of the efficacy of moclobemide and fluvoxamine in elderly patients with a severe depressive episode, European Psychiatry: the Journal of the Association of European Psychiatrists, 8, 319, 10.1017/S0924933800000705 · DOI
  9. Bocksberger, 1992, Comparison of the efficacy and tolerability of moclobemide and fluvoxamine in elderly patients, Clinical Neuropharmacology, 15(1 Pt B), 146, 10.1097/00002826-199202001-00282 · doi:10.1097/00002826-199202001-00282
  10. Bougerol, 1992, Efficacy and tolerability of moclobemide compared with fluvoxamine in depressive disorder (DSM III) A French/Swiss double-blind trial, Psychopharmacology, 106[Suppl], S102, 10.1007/BF02246249 · DOI
  11. Bramanti, 1988, An Italian multicenter experience with fluvoxamine, a new antidepressant drug, versus imipramine, Current Therapeutic Research, Clinical & Experimental., 43, 718
  12. Brown, 1986, Pituitary-adrenocortical hyperfunction and intolerance to fluvoxamine, a selective serotonin uptake inhibitor, American Journal of Psychiatry, 143, 88, 10.1176/ajp.143.1.88 · doi:10.1176/ajp.143.1.88
  13. Brunner, 1994, A randomised, parallel group comparison of fluvoxamine and amineptine in patients with marked depression, British Journal of Clinical Research, 5, 101
  14. Amin, 1984, Fluvoxamine:antidepressant effects confirmed in a placebo-controlled international study, Clinical Neuropharmacology, 7[Suppl 1], 580
  15. Cassano, 1986, Use of a standardized documentation system (BLIPS/BDP) in the conduct of a multicenter international trial comparing fluvoxamine, imipramine, and placebo, Psychopharmacology Bulletin, 22, 52
  16. Conti, 1989, Clinical predictors of response to fluvoxamine, imipramine, and placebo, New Trends in Experimental and Clinical Psychiatry, 5, 221
  17. Conti, 1987, Therapeutic response in subtypes of major depression, New Trends in Experimental and Clinical Psychiatry, 3, 101
  18. Dominguez, 1985, A double-blind placebo-controlled study of fluvoxamine and imipramine in depression, Journal of Clinical Psychiatry, 46, 84
  19. Lapierre, 1987, Treatment of major affective disorder with fluvoxamine, Journal of Clinical Psychiatry, 48, 65
  20. Norton, 1984, A double-blind comparison of fluvoxamine, imipramine and placebo in depressed patients, Journal of Affective Disorders, 7, 297, 10.1016/0165-0327(84)90051-X · DOI
  21. Ottevanger, 1991, The efficacy of fluvoxamine in patients with severe depression, British Journal of Clinical Research, 2, 125
  22. Ottevanger, 1994, The efficacy of fluvoxamine in patients with severe depression, Progress in Neuro-Psychopharmacology & Biological Psychiatry, 18, 731, 10.1016/0278-5846(94)90080-9 · DOI
  23. Ottevanger, 1991, The efficacy of fluvoxamine in patients with severe depression, Psychologie Medicale, 23, 1639
  24. Wagner, 1986, Influence of concomitant psychotropic medication on the efficacy and tolerance of fluvoxamine, Advances in Pharmacotherapy, 2, 34
  25. Wakelin, 1986, Fluvoxamine in the treatment of the older depressed patient; double-blind, placebo-controlled data, International Clinical Psychopharmacology, 1, 221, 10.1097/00004850-198607000-00005 · DOI
  26. Claghorn, 1996, Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients, Journal of Clinical Psychopharmacology, 16, 113, 10.1097/00004714-199604000-00003 · DOI
  27. Clerc, 2001, Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: A comparison with fluvoxamine, International Clinical Psychopharmacology, 16, 145, 10.1097/00004850-200105000-00003 · DOI
  28. Coleman, 1982, Fluvoxamine maleate, a serotonergic antidepressant; A comparison with chlorimipramine, Progress in Neuro-Psychopharmacological & Biological Psychiatry, 6, 475, 10.1016/S0278-5846(82)80132-2 · DOI
  29. Dalery, 2003, Fluvoxamine versus fluoxetine in major depressive episode: A double-blind randomised comparison, Human Psychopharmacology, 18, 379, 10.1002/hup.490 · DOI
  30. Strik, 1998, Cardiac side-effects of two selective serotonin reuptake inhibitors in middle-aged and elderly depressed patients, International Clinical Psychopharmacology, 13, 263, 10.1097/00004850-199811000-00004 · doi:10.1097/00004850-199811000-00004
  31. Wilde, 1983, Clinical trials of fluvoxamine vs chlorimipramine with single and three times daily dosing, British Journal of Clinical Pharmacology, 15, 427S
  32. Dick, 1983, A double-blind comparative study of the clinical efficacy of fluvoxamine and chlorimipramine, British Journal of Clinical Pharmacology, 15, 419S
  33. Fabre, 1996, Fluvoxamine versus imipramine and placebo: A double-blind comparison in depressed patients, International Clinical Psychopharmacology, 11, 119
  34. Fabre, 1992, Fluvoxamine in the treatment of depression - A double-blind comparison with imipramine and placebo in outpatients with major depression, Clinical Neuropharmacology, 15, 416, 10.1097/00002826-199202001-00809 · doi:10.1097/00002826-199202001-00809
  35. Feighner, 1989, A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression, International Clinical Psychopharmacology, 4, 239, 10.1097/00004850-198907000-00006 · DOI
  36. Gonul, 1999, Selective serotonin reuptake inhibitors: discontinuation rates due to side effects, European Neuropsychopharmacology, 9(Suppl 5), 215, 10.1016/S0924-977X(99)80132-1 · doi:10.1016/s0924-977x(99)80132-1
  37. Guy, 1984, A double-blind clinical trial of fluvoxamine and imipramine in patients with primary depression, Psychopharmacology Bulletin, 20, 73
  38. Hackett D Salinas E Desmet A Efficacy and safety of venlafaxine vs. fluvoxamine in outpatients with major depression 11th European College of Neuropsychopharmacology Congress 1998 · DOI
  39. Hackett D Salinas E Desmet A Efficacy and safety of venlafaxine vs. fluvoxamine in outpatients with major depression 11th European College of Neuropsychopharmacology Congress 1998 · DOI
  40. Haffmans, 1996, Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study The lucifer group, International Clinical Psychopharmacology, 11, 157, 10.1097/00004850-199609000-00002 · DOI
  41. Timmerman L Haffmans PMJ Hoogduin CA Citalopram in major depression: a comparative study with Fluvoxamine, Preliminary results Past, Present and Future of Psychiatry (IX World Congress of Psychiatry - 9th 1993 Rio de Janiero, Brazil) River Edge, NJ World Scientific 1994 982 6 · doi:10.1142/9789814440912_0212
  42. Harris, 1991, Fluvoxamine versus amitriptyline in depressed hospital out-patients: a multicentre double-blind comparative trial, British Journal of Clinical Research, 2, 88
  43. Whitehead, 1992, Fluvoxamine in the treatment of depressive illness. A series of double-blind hospital based comparative studies carried out in the UK, British Journal of Clinical Practice, 46, 21
  44. Itil, 1983, A double-blind placebo-controlled study of fluvoxamine and imipramine in out-patients with primary depression, British Journal of Clinical Pharmacology, 15(Suppl 3), 433S
  45. Kasper, 1993, Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects, European Neuropsychopharmacology, 3, 13, 10.1016/0924-977X(93)90290-3 · DOI
  46. Kasper, 1991, Therapeutic sleep deprivation and antidepressant medication in patients with major depression, European Neuropsychopharmacology, 1, 107, 10.1016/0924-977X(91)90711-3 · DOI
  47. Kasper, 1992, Auditory evoked potentials and treatment with specific acting antidepressants, Clinical Neuropharmacology, 15, 152, 10.1097/00002826-199202001-00293 · doi:10.1097/00002826-199202001-00293
  48. Kasper, 1992, Plasma levels of fluvoxamine and maprotiline and clinical response in major depression, Pharmacopsychiatry, 25, 106
  49. Kasper, 1990, Response to total sleep deprivation before and during treatment with fluvoxamine or maprotiline in patients with major depression; results of a double-blind study, Pharmacopsychiatry, 23, 135, 10.1055/s-2007-1014496 · DOI
  50. Kasper, 1989, Stimulation with dl-fenfluramine and antidepressive medication in major depressed inpatients, Pharmacopsychiatry, 22, 201
  51. Kato, 2006, Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients, Neuropsychobiology, 53, 186, 10.1159/000094727 · DOI · Paper page
  52. Kato, 2005, Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism, International Clinical Psychopharmacology, 20, 151, 10.1097/00004850-200505000-00005 · DOI
  53. Kato, 2004, Clinical comparison of paroxetine and fluvoxamine considering of the serotonin transporter promoter polymorphism in patients with affective disorder, International Clinical Psychopharmacology, 19, 175, 10.1097/00004850-200405000-00012 · DOI
  54. Kavoussi, 1999, Prolactin response to d-fenfluramine in major depression before and after treatment with serotonin reuptake inhibitors, Biological Psychiatry, 45, 295, 10.1016/S0006-3223(98)00147-4 · doi:10.1016/s0006-3223(98)00147-4
  55. Kiev, 1997, A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients, Journal of Clinical Psychiatry, 58, 146, 10.4088/JCP.v58n0402 · DOI · Paper page
  56. Koetsier, 2002, CPT performance in major depressive disorder before and after treatment with imipramine or fluvoxamine, Journal of Psychiatric Research, 36, 391, 10.1016/S0022-3956(02)00026-2 · DOI
  57. Volkers, 2004, Effects of imipramine, fluvoxamine,and depressive mood on autonomic cardiac functioning in major depressive disorder, Pharmacopsychiatry, 37, 18, 10.1055/s-2004-815470 · DOI
  58. Kostiukova, 2003, Comparative efficacy and tolerance of fluvoxamine and amitriptyline in the treatment of moderate and severe depression in mental hospital, Zhurnal Nevrologii i Psikhiatrii Imeni SS Korsakova, 103, 24
  59. Brady, 1994, A comparison of the effects of imipramine and fluvoxamine on the thyroid axis, Biological Psychiatry, 36, 778, 10.1016/0006-3223(94)90092-2 · DOI
  60. Johnson, 1993, Effect of fluvoxamine, imipramine and placebo on catecholamine function in depressed outpatients, Journal of Psychiatric Research, 27, 161, 10.1016/0022-3956(93)90004-L · doi:10.1016/0022-3956(93)90004-l
  61. Laird, 1993, Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients, Journal of Clinical Psychiatry, 54, 224
  62. Lydiard, 1989, Fluvoxamine, imipramine, and placebo in the treatment of depressed outpatients: effects on depression, Psychopharmacology Bulletin, 25, 68
  63. March, 1990, A double-blind, placebo-controlled trial of fluvoxamine versus imipramine in outpatients with major depression, Journal of Clinical Psychiatry, 51, 200
  64. Mendonca Lima, 1997, Maprotiline versus fluvoxamine: comparison of their effects on the hypothalamo-hypophyseal-thyroid axis, Encephale, 23, 48
  65. Miller, 2001, Noradrenergic function and clinical outcome in antidepressant pharmacotherapy, Neuropsychopharmacology, 24, 617, 10.1016/S0893-133X(00)00232-3 · DOI
  66. Moon, 1991, The effects of psychomotor performance of fluvoxamine versus mianserin in depressed patients in general practice, British Journal of Clinical Practice, 45, 259
  67. Mullin, 1998, A double-blind comparison of fluvoxamine and dothiepin in the treatment of major affective disorder, British Journal of Clinical Practice, 42, 51
  68. Whitehead, 1992, Fluvoxamine in the treatment of depressive illness. A series of double-blind hospital based comparative studies carried out in the UK, British Journal of Clinical Practice, 46, 21
  69. Murasaki, 1998, Clinical evaluation of sme3110 (fluvoxamine maleate) in the treatment of depression and depressive state: a double-blind, comparative study with amitriptyline, Rinsyoiyaku (Journal of clinical therapeutics & medicine), 14, 951
  70. Kupfer, 1991, Fluvoxamine versus desipramine: Comparative polysomnographic effects, Biological Psychiatry, 29, 23, 10.1016/0006-3223(91)90208-4 · DOI · Paper page
  71. Nathan, 1990, The role of neuropharmacologic selectivity in antidepressant action: fluvoxamine versus desipramine, Journal of Clinical Psychiatry, 51, 367
  72. Nemeroff C Ninan P Ballenger J Feighner J Greist J Patterson W Comparison of the safety and tolerance of fluvoxamine and sertraline in depressed outpatients 8th ECNP (European College of Neuropsychopharmacology) Congress Venice, Italy 1995 · DOI
  73. Nemeroff, 1995, Double-blind multicenter comparison of fluvoxamine versus sertraline in the treatment of depressed outpatients, Depression, 3, 163, 10.1002/depr.3050030402 · DOI
  74. Otsubo, 2005, A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression, Pharmacopsychiatry, 38, 30, 10.1055/s-2005-837769 · doi:10.1055/s-2005-837769
  75. Ottevanger, 1995, Fluvoxamine and clomipramine in depressed hospitalised patients: results from a randomised, double-blind study, Encephale, 21, 317
  76. Perez, 1990, A double-blind, randomized comparison of fluvoxamine with mianserin in depressive illness, Current Medical Research and Opinion, 12, 234, 10.1185/03007999009111652 · DOI · Paper page
  77. Whitehead, 1992, Fluvoxamine in the treatment of depressive illness. A series of double-blind hospital based comparative studies carried out in the UK, British Journal of Clinical Practice, 46, 21
  78. Rahman, 1991, A double-blind, randomised comparison of fluvoxamine with dothiepin in the treatment of depression in elderly patients, British Journal of Clinical Practice, 45, 255
  79. Whitehead, 1992, Fluvoxamine in the treatment of depressive illness. A series of double-blind hospital based comparative studies carried out in the UK, British Journal of Clinical Practice, 46, 21
  80. Rapaport M Coccaro E Sheline Y Holland P Perse T Fabre L Bradford D Comparison of fluvoxamine and fluoxetine in major depression 8th ECNP (European College of Neuropsychopharmacology) Congress Venice, Italy 1995 · doi:10.1016/0924-977x(95)90453-k
  81. Rapaport, 1996, A comparison of fluvoxamine and fluoxetine in the treatment of major depression, Journal of Clinical Psychopharmacology, 16, 373, 10.1097/00004714-199610000-00005 · DOI
  82. Rechlin, 1994, The effect of amitriptyline, doxepin, fluvoxamine, and paroxetine treatment on heart rate variability, Journal of Clinical Psychopharmacology, 14, 392, 10.1097/00004714-199412000-00004 · DOI
  83. Remick, 1994, Comparison of fluvoxamine and amitriptyline in depressed outpatients, Current Therapeutic Research, Clinical and Experimental, 55, 243, 10.1016/S0011-393X(05)80168-7 · DOI
  84. Rossini, 2002, Sertraline versus fluvoxamine in the treatment of elderly patients with major depression: A double-blind, randomised trial, European Neuropsychopharmacology, 12, S251, 10.1016/S0924-977X(02)80321-2 · doi:10.1016/s0924-977x(02)80321-2
  85. Rossini, 2005, Sertraline versus fluvoxamine in the treatment of elderly patients with major depression: A double-blind, randomized trial, Journal of Clinical Psychopharmacology, 25, 471, 10.1097/01.jcp.0000177548.28961.e7 · DOI
  86. Rota, 2005, Neuroendocrine (HPA axis) and clinical correlates during fluvoxamine and amitriptyline treatment, Psychiatry Research, 133, 281, 10.1016/j.psychres.2003.12.030 · DOI
  87. Schoemaker, 2002, First, randomized, double-blind comparison of mirtazapine (15-45 mg) and fluvoxamine (50-150 mg) in the treatment of depression, International Journal of Neuropsychopharmacology, 5, 140
  88. Tourigny-Rivard M Nair N Vincent P Fluvoxamine versus desipramine in elderly patients with major depression: A double-blind comparison 9th ECNP (European College of Neuropsychopharmacology) Congress Amsterdam, Netherlands 1996 · doi:10.1016/0924-977x(96)83081-1
  89. Ueda, 2002, Plasma levels of catecholamine metabolites predict the response to sulpiride or fluvoxamine in major depression, Pharmacopsychiatry., 35, 175, 10.1055/s-2002-34116 · DOI
  90. Katz, 1993, Drug treatment of depression in the frail elderly, discussion of the NIH consensus development conference on the diagnosis and treatment of depression late-life, Psychopharmacology Bulletin, 29, 101
  91. Wagner, 1994, Fluvoxamine. A review of its safety profile in world-wide studies, International Clinical Psychopharmacology, 9, 222, 10.1097/00004850-199400940-00001 · DOI
  92. Zohar, 2003, Fluvoxamine as effective as clomipramine against symptoms of severe depression: results from a multicentre, double-blind study, Human Psychopharmacology, 18, 113, 10.1002/hup.442 · DOI
  93. Baicsher, 1991, Clinical use of fluvoxamine in selected outpatients with depression, anxiety, and eating disorders, Pakistan Journal of Clinical Psychiatry, 3, 143
  94. Bellini, 1992, A standardized treatment for delusional depression: Preliminary results, Clinical Neuropharmacology, 15(1 Pt B), 413, 10.1097/00002826-199202001-00802 · doi:10.1097/00002826-199202001-00802
  95. Blier, 1997, Selective activation of postsynaptic 5-HT(1A) receptors induces rapid antidepressant response, Neuropsychopharmacology, 16(5), 333, 10.1016/S0893-133X(96)00242-4 · DOI · Paper page
  96. Davis, 1991, Deuterium-labelled p-tyramine challenge test and phenolsulfotransferase activity in depressed patients- Failure to replicate decreased p-tyramine conjugation in depression, Progress in Neuro-psychopharmacology & Biological Psychiatry, 15, 241, 10.1016/0278-5846(91)90087-H · doi:10.1016/0278-5846(91)90087-h
  97. Jonghe, 1991, Randomized double-blind study of fluvoxamine and maprotiline in treatment of depression, Pharmacopsychiatry, 24, 21, 10.1055/s-2007-1014428 · DOI
  98. Kemp, 2002, Diagnosis at the first episode to differentiate antidepressant treatment responses in patients with mood and anxiety disorders, Psychopharmacology, 160, 67, 10.1007/s00213-001-0947-4 · DOI
  99. Wilde, 1982, Fluvoxamine and chlorimipramine in endogenous depression, Journal of Affective Disorders, 4, 249, 10.1016/0165-0327(82)90009-X · DOI
  100. Emrich, 1987, Serotonin reuptake inhibition vs norepinephrine reuptake inhibition: a double-blind differential-therapeutic study with fluvoxamine and oxaprotiline in endogenous and neurotic depressives, Pharmacopsychiatry, 20, 60, 10.1055/s-2007-1017076 · DOI
  101. Entsuah, 2002, A critical examination of the sensitivity of unidimensional subscales derived from the Hamilton Depression Rating Scale to antidepressant drug effects, Journal of Psychiatric Research, 36, 437, 10.1016/S0022-3956(02)00024-9 · DOI
  102. Franchini, 1997, Four-year follow-up study of sertraline and fluvoxamine in long-term treatment of unipolar subjects with high recurrence rate, Journal of Affective Disorders, 58, 233, 10.1016/S0165-0327(99)00113-5 · DOI
  103. Gasperini, 1992, Perspectives in clinical psychopharmacology of amitriptyline and fluvoxamine A double-blind study in depressed inpatients, Neuropsychobiology, 26, 186, 10.1159/000118918 · DOI
  104. Gonella, 1990, Fluvoxamine and imipramine in the treatment of depressive patients: a double-blind controlled study, Current Medical Research and Opinion, 12, 177, 10.1185/03007999009111499 · DOI
  105. Goto, 2006, Treatment of anxiety and depression-related vertigo and dizziness with SSRIs and SNRIs, Equilibrium Research, 65, 17, 10.3757/jser.65.17 · DOI
  106. Guelfi, 1983, A double-blind controlled clinical trial comparing fluvoxamine with imipramine, British Journal of Clinical Pharmacology, 15, 411
  107. Guelfi, 1987, Fluvoxamine and imipramine: results of a long-term controlled trial, International Clinical Psychopharmacology, 2, 103, 10.1097/00004850-198704000-00002 · DOI
  108. Harris, 1991, Maintenance antidepressants and weight gain: A comparison of fluvoxamine and amitriptyline, British Journal of Clinical Research, 2, 81
  109. Hewer, 1995, Cardiovascular effects of fluvoxamine and maprotiline in depressed patients, European Archives of Psychiatry and Clinical Neuroscience, 246, 1, 10.1007/BF02191808 · DOI
  110. Hewer, 1994, Effects of fluvoxamine and maprotiline on ECG parameters, Nervenheilkunde, 13, 375
  111. Hochberg, 1995, Electrocardiographic findings during extended clinical trials of fluvoxamine in depression: one year's experience, Pharmacopsychiatry, 28, 253, 10.1055/s-2007-979612 · DOI
  112. Khan, 1989, Onset of response in relation to outcome in depressed outpatients with placebo and imipramine, Journal of Affective Disorders, 17, 33, 10.1016/0165-0327(89)90021-9 · DOI
  113. Khan, 1991, Chronicity of depressive episode in relation to antidepressant-placebo response, Neuropsychopharmacology, 4, 125
  114. Klok, 1981, Fluvoxamine and clomipramine in depressed patients: A double blind clinical study, Acta Psychiatrica Scandinavica, 64, 1, 10.1111/j.1600-0447.1981.tb00756.x · DOI
  115. Manfredonia, 1992, Memory impairments in depression, Clinical Neuropharmacology, 15, 568, 10.1097/00002826-199202001-01108 · doi:10.1097/00002826-199202001-01108
  116. Muck-Seler, 1991, Effect of antidepressant treatment on platelet 5-HT content and relation to therapeutic outcome in unipolar depressive patients, Journal of Affective Disorders, 23, 157, 10.1016/0165-0327(91)90028-Q · DOI
  117. Murasaki, 1998, A late clinical phase ii study of sme3110 (fluvoxamine maleate), a selective serotonin reuptake inhibitor, in the treatment of depression and depressive state: an investigation of an optimal dose range using imipramine as a comparator, Rinsyoiyaku (Journal of clinical therapeutics & medicine), 14, 919
  118. Namiki, 1996, A clinical phase iii study of sme3110 (fluvoxamine maleate) in depressed patients at the department of internal medicine: a double-blind, comparative study with trazodone hydrochloride, Rinsyoiyaku, 12, 651
  119. Nicolini H Herrera K Pez F Camarena B Guajardo R De la Fuente JR Temperament, character, and molecular genotypes as predictors of antidepressant response XXth Collegium Internationale Neuro psychopharmacologicum Melbourne, Australia; 1996 · doi:10.1016/0924-977x(96)87893-x
  120. Nolen, 1998, Treatment strategy in depression I Non-tricyclic and selective reuptake inhibitors in resistant depression: a double-blind partial crossover study on the effects of oxaprotiline and fluvoxamine, Acta Psychiatrica Scandinavica, 78, 668, 10.1111/j.1600-0447.1988.tb06402.x · DOI
  121. Phanjoo, 1991, Double-blind comparative multicentre study of fluvoxamine and mianserin in the treatment of major depressive episode in elderly people, Acta Psychiatrica Scandinavica, 83, 476, 10.1111/j.1600-0447.1991.tb05579.x · DOI
  122. Poldinger, 1991, A functional-dimensional approach to depression: serotonin deficiency as a target syndrome in a comparison of 5-hydroxytryptophan and fluvoxamine, Psychopathology, 24, 53, 10.1159/000284698 · DOI
  123. Price, 1989, Effects of desipramine and fluvoxamine treatment on the prolactin response to tryptophan. Serotonergic function and the mechanism of antidepressant action, Archives of General Psychiatry, 46, 625, 10.1001/archpsyc.1989.01810070051009 · DOI
  124. Price, 1986, Variability of response to lithium augmentation in refractory depression, American Journal of Psychiatry, 143, 1387, 10.1176/ajp.143.11.1387 · DOI
  125. Ravindran, 1995, Stressful life events and coping styles in relation to dysthymia and major depressive disorder: Variations associated with alleviation of symptoms following pharmacotherapy, Progress in Neuro-Psychopharmacology & Biological Psychiatry, 19, 637, 10.1016/0278-5846(95)00108-8 · DOI
  126. Sacchetti, 1994, Are SSRI antidepressants a clinically homogeneous class of compounds?, Lancet, 344, 126, 10.1016/S0140-6736(94)91310-2 · DOI
  127. Sacchetti, 1997, Effectiveness of fluvoxamine and paroxetine in major depressives with psychotic features, Human Psychopharmacology, 12, 277, 10.1002/(SICI)1099-1077(199705/06)12:3<277::AID-HUP858>3.0.CO;2-E · doi:10.1002/(sici)1099-1077(199705/06)12:3<277::aid-hup858>3.0.co;2-e
  128. Schanda, 1979, Repolarisation disturbances in the ECG under antidepressant drugs. A comparison of two drugs, differing in chemical structure and pharmacological profile, Pharmakopsychiatrie, Neuro-Psychopharmakologie, 12, 338, 10.1055/s-0028-1094628 · doi:10.1055/s-0028-1094628
  129. Serretti, 2004, Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders, American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics, 129, 36, 10.1002/ajmg.b.30027 · DOI
  130. Sheline, 1997, Correlated reductions in cerebrospinal fluid 5-HIAA and MHPG concentrations after treatment with selective serotonin reuptake inhibitors, Journal of Clinical Psychopharmacology, 17, 11, 10.1097/00004714-199702000-00003 · DOI
  131. Uzunova, 1998, Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine, Proceedings of the National Academy of Sciences of the United States of America, 95, 3239, 10.1073/pnas.95.6.3239 · DOI · Paper page
  132. Vandel, 1995, Fluvoxamine and fluoxetine: Interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients, Pharmacological Research, 31, 347, 10.1016/1043-6618(95)80088-3 · DOI
  133. Birkenhager, 2004, Comparison of two-phase treatment with imipramine or fluvoxamine, both followed by lithium addition, in inpatients with major depressive disorder, American Journal of Psychiatry, 161, 2060, 10.1176/appi.ajp.161.11.2060 · DOI
  134. Broek, 2004, A double-blind randomized study comparing imipramine with fluvoxamine in depressed inpatients, Psychopharmacology, 175, 481, 10.1007/s00213-004-1853-3 · DOI
  135. White, 1990, Fluvoxamine in the treatment of tricyclic-resistant depression, Psychiatric Journal of the University of Ottawa, 15, 156
  136. Yu, 2001, A comparative study of Luvox and amitriptyline in patients with major depression, Medical Journal of Chinese Civil Administration, 13, 227
  137. Zanardi, 2000, Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study, Journal of Clinical Psychiatry, 61, 26, 10.4088/JCP.v61n0107 · DOI
  138. Berlin, 1998, Early predictors of two month response with mianserin and selective serotonin reuptake inhibitors and influence of definition of outcome on prediction, European Psychiatry, 13, 138, 10.1016/S0924-9338(98)80137-5 · DOI
  139. Donovan, 1993, The efficacy and tolerability of dothiepin versus serotonin specific reuptake inhibitors in the treatment of depression, European Neuropsychopharmacology, 3, 331, 10.1016/0924-977X(93)90108-X · DOI
  140. Entsuah, 2002, Venlafaxine offers significant therapeutic benefits over existing SSRI treatments irrespective of the patient's depressive duration, European Neuropsychopharmacology, 12 Suppl 3, S238
  141. Faludi, 1989, Fluvoxamine versus maprotiline (Ludiomil) in the treatment of depression, IDeggyogyaszati Szemle, 46, 116
  142. Mallick, 2003, Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo, Journal of clinical psychiatry, 64, 321, 10.4088/JCP.v64n0315 · DOI
  143. Naito, 2007, Gender differences in the clinical effects of fluvoxamine and milnacipran in Japanese major depressive patients, Psychiatry and Clinical Neurosciences, 61, 421, 10.1111/j.1440-1819.2007.01679.x · DOI
  144. Ushiroyama T. Ikeda A. Ueki, 2004, Evaluation of double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients in menopause transition, Journal of Medicine, 35, 151
  145. Anderson, 1994, The efficacy of selective serotonin reuptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants, J Psychopharmacol, 8, 238, 10.1177/026988119400800407 · DOI · Paper page
  146. Anderson, 1998, SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability, Depression and Anxiety, 7 Suppl 1, 11, 10.1002/(SICI)1520-6394(1998)7:1+<11::AID-DA4>3.0.CO;2-I · DOI · Paper page
  147. Anderson, 2000 Mar, Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines.British Association for Psychopharmacology, Journal of Psychopharmacology, 14, 3, 10.1177/026988110001400101 · DOI · Paper page
  148. Anderson, 2001, Guidelines for choice of selective serotonin reuptake inhibitor in depressive illness, Advances in psychiatric treatment, 7, 170, 10.1192/apt.7.3.170 · DOI
  149. American Psychiatric Association, 1994, Diagnostic and Statistical Manual of Mental Disorders
  150. American Psychiatric Association, 2000, Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association, American Journal of Psychiatry, 157, 1
  151. Barbui, 2000, Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD002791 · DOI
  152. Barbui, 2004 Apr, "Wish bias" in antidepressant drug trials?, Journal of Clinical Psychopharmacology, 24, 126, 10.1097/01.jcp.0000115665.45074.0d · DOI
  153. Barbui, 2008, Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials, Canadian Medical Association Journal, 178, 296, 10.1503/cmaj.070693 · DOI
  154. Bhandari, 2004, Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials, Canadian Medical Association Journal, 170, 477
  155. Bucher, 1997, The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials, Journal of clinical epidemiology, 50, 683, 10.1016/S0895-4356(97)00049-8 · DOI · Paper page
  156. Buchkowsky, 2004, Industry sponsorship and authorship of clinical trials over 20 years, Annals of Pharmacotherapy, 38, 579, 10.1345/aph.1D267 · DOI
  157. Burton, 1991, A review of fluvoxamine and its uses in depression, International Clinical Psychopharmacology, 6 Suppl 3, 1-17; discussio
  158. Churchill, 2009, Reboxetine versus other antidepressive agents for depression, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD007852 · DOI
  159. Cipriani, 2005, Fluoxetine versus other types of pharmacotherapy for depression, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD004185.pub2 · DOI
  160. Cipriani, 2006, Are all antidepressants really the same? The case of fluoxetine: a systematic review, Journal of Clinical Psychiatry, 67, 850, 10.4088/JCP.v67n0601 · DOI
  161. Cipriani, 2007, Paroxetine versus other anti-depressive agents for depression, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006531 · DOI
  162. Cipriani, 2007, Venlafaxine versus other anti-depressive agents for depression, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006530 · DOI
  163. Cipriani, 2009, Sertraline versus other antidepressive agents for depression, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006117.pub2 · DOI · Paper page
  164. Ciuna, 2004, Are we going to increase the use of antidepressants up to that of benzodiazepines?, European Journal of Clinical Pharmacology, 60, 629, 10.1007/s00228-004-0810-8 · DOI
  165. Claassen, 1977, Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor, British Journal of Pharmacology, 60, 505, 10.1111/j.1476-5381.1977.tb07528.x · DOI · Paper page
  166. Depression Guideline, 1993, Depression in primary care: Vol 2
  167. Dozois, 2004, Depression, 259
  168. Edwards, 1999, Systematic review and guide to selection of selective serotonin reuptake inhibitors, Drugs, 57, 507, 10.2165/00003495-199957040-00005 · DOI · Paper page
  169. Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, British Medical Journal, 315, 629, 10.1136/bmj.315.7109.629 · DOI · Paper page
  170. Ellis, 2004, Australian and New Zealand clinical practice guidelines for the treatment of depression, Australian and New Zealand Journal of Psychiatry, 38, 389, 10.1080/j.1440-1614.2004.01377.x · DOI · Paper page
  171. Feighner, 1972, Diagnostic criteria for use in psychiatric research, Archives of General Psychiatry, 26, 57, 10.1001/archpsyc.1972.01750190059011 · DOI · Paper page
  172. Fuller, 1987, Serotonin reuptake blockers in vitro and in vivo, Journal of Clinical Psychopharmacology, 7, 36S
  173. Furukawa, 2002, Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review, British Medical Journal, 325, 991, 10.1136/bmj.325.7371.991 · DOI
  174. Furukawa, 2007, Association between unreported outcomes and effect size estimates in Cochrane meta-analyses, JAMA, 297, 468, 10.1001/jama.297.5.468-b · DOI
  175. Geddes, 2006, SSRIs versus other antidepressants for depressive disorder, Cochrane Database of Systematic Reviews
  176. Goldberg, 1991, Common mental disorders : a bio-social model
  177. Guaiana, 2005, Antidepressant drug consumption and public health indicators in Italy, 1955 to 2000, Journal of Clinical Psychiatry, 66, 750, 10.4088/JCP.v66n0612 · DOI
  178. Guaiana, 2007, Amitriptyline for depression, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD004186.pub2 · DOI · Paper page
  179. Guy, 1976, Clinical Global Impressions - ECDEU Asessment Manual Psychopharmacology (DHEW Publ No ADM 76-338)
  180. Hall, 1995, Global Assessment of Functioning - a modified scale, Psychosomatics, 36, 267, 10.1016/S0033-3182(95)71666-8 · DOI · Paper page
  181. Hamilton, 1960, A rating scale of depression, Journal of Neurology, 23, 56
  182. Hammad, 2006, Suicidality in pediatric patients treated with antidepressant drugs, Archives of General Psychiatry, 63, 332, 10.1001/archpsyc.63.3.332 · DOI · Paper page
  183. Higgins, 2003, Measuring inconsistency in meta-analyses, British Medical Journal, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
  184. Higgins, 2008. Available from www.cochrane-handbook.org, Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]., 10.1002/9780470712184 · DOI · Paper page
  185. Imperadore, 2007, Citalopram versus other anti-depressive agents for depression, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006534 · DOI
  186. Ioannidis, 2006, Indirect comparisons: the mesh and mess of clinical trials, Lancet, 368, 1470, 10.1016/S0140-6736(06)69615-3 · DOI
  187. Khan, 2003, Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports, Neuropsychopharmacology, 28, 552, 10.1038/sj.npp.1300059 · DOI · Paper page
  188. Lecrubier, 1996 Sep, Clinical efficacy of milnacipran: placebo-controlled trials, International Clinical Psychopharmacology, 11, 29, 10.1097/00004850-199609004-00004 · DOI
  189. Linde, 2008, St John's wort for major depression, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD000448.pub3 · DOI · Paper page
  190. Lopez-Ibor, 1996, Milnacipran and selective serotonin reuptake inhibitors in major depression, International Clinical Psychopharmacology, 11, 41, 10.1097/00004850-199609004-00006 · DOI
  191. Lu, 2006, Assessing evidenceinconsistency in mixed treatmentcomparisons, Journal of American StatisticalAssociation, 101, 447–59
  192. Mackay, 1997, A comparison if fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies, Pharmacoepidemiology and Drug Safety, 6, 235–246, 10.1002/(SICI)1099-1557(199707)6:4<235::AID-PDS293>3.0.CO;2-3 · DOI
  193. Montgomery, 2004, An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia, Controlled clinical trials, 25, 598, 10.1016/j.cct.2004.09.002 · DOI
  194. Mottram, 2006, Antidepressants for depressed elderly, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD003491.pub2 · DOI · Paper page
  195. Nakagawa, 2007, Milnacipran versus other anti-depressive agents for depression, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006529 · DOI
  196. NICE, 2004, Depression: management of depression in primary and secondary care
  197. Nose, 2007, Duloxetine versus other anti-depressive agents for depression, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006533 · DOI
  198. Okamura, 2006, Remission rates with milnacipran 100mg/day and 150 mg/day in the long-term treatment of major depression, Clinical Drug Investigation, 26, 135, 10.2165/00044011-200626030-00003 · DOI
  199. Perucca, 1994, Clinical pharmacokinetics of fluvoxamine, Clinical Pharmacokinetics, 27, 175, 10.2165/00003088-199427030-00002 · DOI
  200. Procyshyn, 2004, Prevalence and outcomes of pharmaceutical industry-sponsored clinical trials involving clozapine, risperidone, or olanzapine, Canadian Journal of Psychiatry, 49, 601, 10.1177/070674370404900905 · DOI

200 of 217 shown

Cited by

See all 209

Metadata

Authors
Omori, I. M., Watanabe, N., Nakagawa, A., Cipriani, A., Barbui, C., McGuire, H., Churchill, R., & Furukawa, T. A.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2010-03-17
Volume
2013
Issue
9
Pages
CD006114-CD006114
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W4210997607
Cited by
209
References
28
FWCI
2.25
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fluvoxamine versus other anti-depressive agents for depression. https://app.cochat.ai/papers/10.1002/14651858.cd006114.pub2
The paper
Omori, I. M., Watanabe, N., Nakagawa, A., Cipriani, A., Barbui, C., McGuire, H., Churchill, R., & Furukawa, T. A. (2010). Fluvoxamine versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd006114.pub2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.